Mumbai, Aug 11 — Zydus Lifesciences on Tuesday reported a 36 per cent year-on-year (YoY) decline in its consolidated net profit for the first quarter of the current financial year (Q1 FY27).
The Ahmedabad-based drugmaker said its net profit fell 35.9 per cent year-on-year to Rs 940 crore in the June quarter, compared with Rs 1,467 crore in the corresponding period last financial year (Q1 FY26), according to its stock exchange filing.
The pharmaceutical major’s revenue from operations rose 22 per cent to Rs 8,017 crore during the quarter, up from Rs 6,574 crore a year ago.
However, profitability came under pressure. Earnings before interest, taxes, depreciation and amortisation (EBITDA) slipped 7.6 per cent to Rs 1,930 crore from Rs 2,089 crore in the year-ago period.
Consequently, the EBITDA margin contracted significantly to 24.1 per cent from 31.8 per cent in the corresponding quarter of the previous financial year.
Despite the weaker earnings performance, investors appeared largely unfazed. Following the results announcement, shares of Zydus Lifesciences were trading at Rs 1,126, up 0.63 per cent, or Rs 7, from the previous close.
The stock has delivered mixed performance across different time frames. Over the past five trading sessions, it gained 1.41 per cent, or Rs 15.70.
On a one-month basis, however, the stock was down 0.52 per cent, or Rs 5.90. Over the last six months, Zydus shares have rallied 25.43 per cent, adding Rs 228.40 in value.
On a year-to-date basis, the stock has risen 23.20 per cent, or Rs 212.25.
Zydus Lifesciences, formerly known as Cadila Healthcare, is one of India's leading pharmaceutical companies.
Founded in 1952 and headquartered in Ahmedabad, the company rebranded itself as Zydus Lifesciences in 2022.
Led by Chairman Pankaj R. Patel, the company has a presence in more than 50 countries and operates over 30 manufacturing facilities worldwide.
The company has a diversified business spanning generic medicines, active pharmaceutical ingredients (APIs), vaccines, biosimilars and specialty products.
Through its subsidiary Zydus Wellness, it also owns several consumer brands including Glucon-D, Sugar Free, Complan, Nycil and Everyuth.